http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2037188-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97ddd4d1d0ebc8a7d2c8e7d214d08cf3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-535 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D315-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-94 |
| filingDate | 1991-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c0d365055b71f86aabc1a8ed91813ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a04a3c0866cf632d710b179058d73f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6300a72a477b9b2ee1c53f63d1fb84ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3792b851249250790a8b757abb8cf14c |
| publicationDate | 1991-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2037188-A1 |
| titleOfInvention | Agent for treating disorders from cerebral neuro-degeneration |
| abstract | ABSTRACT AGENT FOR TREATING DISORDERS FROM CEREBRAL NEURO-DEGENERATION A therapeutic agent for alleviating disorders caused by nerve cell degeneration in the brain which contains a cyclopropachromen derivative represented by the following general formula (I): (I) wherein n is an integer of from 2 to 5; the carbon atom in the -(CH2)n- moiety may be option-ally substituted with a methyl group or a hydroxyl group; Rl and R2 independentlY represent a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a phenyl group or an aralkyl group having 7 to 10 carbon atoms; or alternatively R1 and R2 form together with the nitrogen atom to which they are attached, a morpholino group, a thiomorpholino group, a pyrrolidinyl group, a piperidinyl group, a homopiperidinyl group, a piperazinyl group, a homopiperazinyl group, an N-alkylpiperazinyl group, N-alkylhomopiperazinyl group, an N-hydroxyalkylpiperazinyl group or a pyrrolidonyl group or alternatively R1 and R2 form together with the nitrogen atom to which they are attached, and further a carbon atom to which said nitrogen atom is bound, a pyrrolitidinyl group; Al and A2 independently represent a hydrogen atom, a hydroxyl group, a halogen atom, an optionally halogenated alkyl group having 1 to 5 carbon atoms, an optionally substituted alkoxy group, an acyloxy group, a carbamyloxy group or an optionally substituted carboxyl group; and Bl and B2 independently represent a hydrogen atom, a halogen atom, a nitro group, a cyano group, an optionally halogenated alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms or an optionally substituted carboxyl group; or a pharmaceutically acceptable salt thereof as an active ingredient, together with a pharmaceutical carrier or adjuvant. |
| priorityDate | 1990-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 98.